This meta-analysis confirmed that regimens containing PD-1- or PD-L1-targeting agents have clinical utility and acceptable side-effect profiles when used in the treatment of triple-negative breast cancer. Future research should explore combination therapies to enhance efficacy and combat resistance. This evidence concerns the gene CD274 and triple-negative breast carcinoma.